Measurement of CI-979 (a candidate drug for the treatment of age-related disorders of cognition) in human plasma by capillary gas chromatography with nitrogen-selective detection.
A specific and highly sensitive method for the measurement of CI-979 in human plasma is described. The compound and internal standard were extracted from alkalinized plasma with methyl tert.-butyl ether and analyzed by capillary gas chromatography with nitrogen-selective detection. The method was demonstrated to be accurate and precise. Since the limit of quantitation was 0.10 ng/ml, this method was suitable for clinical pharmacokinetic studies in which subjects received repeated administration of 0.5-2.5 mg CI-979 every 6 h.
Windsor
B L
BL
Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105.
Radulovic
L L
LL
Bockbrader
H N
HN
Chang
T
T
D002849:Chromatography, Gas; D004095:Dihydropyridines / Q000097:blood*; D006801:Humans; D007202:Indicators and Reagents; D010091:Oximes / Q000097:blood*; D011619:Psychotropic Drugs / Q000097:blood*; D012015:Reference Standards; D012997:Solvents
D004095:Dihydropyridines; D007202:Indicators and Reagents; D010091:Oximes; D011619:Psychotropic Drugs; D012997:Solvents; C084978:milameline